Karyopharm announces significant refinancing transactions and amended royalty agreement extending vast majority of its debt maturities into 2028 and 2029

– $148.0 million (86%) of existing convertible notes due in 2025 to be exchanged for $111.0 million of new convertible notes due in 2029 and warrants – – issues new $100.0 million senior secured term loan due in 2028 – – repays principal portion and amends royalty agreement with healthcare royalty – newton, mass. , may 8, 2024 /prnewswire/ -- karyopharm therapeutics inc. (nasdaq: kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced today that it has entered into a series of financing transactions that will extend the company's debt maturities into 2028 and 2029, well beyond the company's planned phase 3 data readouts in 2025.
KPTI Ratings Summary
KPTI Quant Ranking